In vitro methods that can replace animal testing in the identification of skin sensitisers are now a reality. However, as cell culture and related techniques usually rely on animal-derived products, these methods may be failing to address the complete replacement of animals in safety assessment. The objective of this study was to identify the animal-derived products that are used as part of in vitro methods for skin sensitisation testing. Thus, a systematic review of 156 articles featuring 83 different in vitro methods was carried out and, from this review, the use of several animal-derived products from different species was identified, with the use of fetal bovine serum being cited in most of the methods (78%). The use of sera from other animals, monoclonal antibodies and animal proteins were also variously mentioned. While non-animal alternatives are available and methods free of animal-derived products are emerging, most of the current methods reported used at least one animal-derived product, which raises ethical and technical concerns. Therefore, to deliver technically and ethically better in vitro methods for the safety assessment of chemicals, more effort should be made to replace products of animal origin in existing methods and to avoid their use in the development of new method protocols.
NguyenSHDangTPMacPhersonC, et al.Prevalence of patch test results from 1970 to 2002 in a multi-centre population in North America (NACDG). Contact Dermat2008; 58: 101–106.
2.
PeiserMTralauTHeidlerJ, et al.Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects. Current knowledge assembled at an international workshop at BfR, Germany. Cell Mol Life Sci2012; 69: 763–781.
3.
OECD. Test No. 406: Skin sensitisation, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 1992, 9 pp.
4.
OECD. Test No. 429: Skin sensitisation: Local Lymph Node Assay, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 2010, 20 pp.
5.
OECD. Test No. 442A: Skin sensitisation: Local Lymph Node Assay: DA, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 2010, 16 pp.
6.
OECD. Test No. 442B: Skin sensitisation: Local Lymph Node Assay: BrdU-ELISA or -FCM, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 2018, 15 pp.
7.
AndersonSESiegelPDMeadeBJ. The LLNA: a brief review of recent advances and limitations. J Allergy2011; 2011: 424203.
8.
National Research Council. Toxicity testing in the 21st century: a vision and a strategy. Washington, DC: The National Academies Press, 2007, 216 pp.
9.
Anon. Directive 2003/15/EC of the European Parliament and of the Council of 27 February 2003 amending Council Directive 76/768/EEC on the approximation of the laws of the Member States relating to cosmetic products. Off J Euro Union2003; L66: 26–35.
10.
ChengSQuXQinY. Harmonisation of animal testing alternatives in China. Altern Lab Anim2017; 45: 333–338.
11.
KimberIPichowskiJSBettsCJ, et al.Alternative approaches to the identification and characterization of chemical allergens. Toxicol in Vitro2001; 15: 307–312.
12.
MehlingAErikssonTEltzeT, et al.Non-animal test methods for predicting skin sensitization potentials. Arch Toxicol2012; 86: 1273–1295.
13.
CasatiSAschbergerKBarrosoJ, et al.Standardisation of defined approaches for skin sensitisation testing to support regulatory use and international adoption: position of the International Cooperation on Alternative Test Methods. Arch Toxicol2018; 92: 611–617.
14.
OECD. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins. Part 2: Use of the AOP to develop chemical categories and integrated assessment and testing approaches, Series on Testing and Assessment No. 168. Paris, France: Organisation for Economic Co-operation and Development, 2012, 46 pp.
15.
BauchCKolleSNRamirezT, et al.Putting the parts together: combining in vitro methods to test for skin sensitizing potentials. Regul Toxicol Pharmacol2012; 63: 489–504.
16.
BasketterDCasatiSGerberickGF, et al.Skin sensitisation. Altern Lab Anim2005; 33: 83–103.
17.
RovidaCAlépéeNApiAM, et al.Integrated Testing Strategies (ITS) for safety assessment. ALTEX2015; 32: 25–40.
18.
OECD. Guidance Document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitisation. Series on Testing and Assessment No. 256. Paris, France: Organisation for Economic Co-operation and Development, 2016, 24 pp.
19.
JochemsCEvan der ValkJBStafleuFR, et al.The use of fetal bovine serum: ethical or scientific problem?Altern Lab Anim2002; 30: 219–227.
20.
van der ValkJMellorDBrandsR, et al.The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol in Vitro2004; 18: 1–12.
21.
GstraunthalerG. Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX2003; 20: 275–281.
22.
van der ValkJBiebackKButaC, et al.Fetal bovine serum (FBS): past — present — future. ALTEX2018; 35: 99–118.
23.
AebyPAshikagaTBessou-TouyaS, et al.Identifying and characterising chemical skin sensitizers without animal testing: Colipa’s research and method development program. Toxicol in Vitro2010; 24: 1465–1473.
24.
MaxwellGAleksicMAptulaA, et al.Assuring consumer safety without animal testing: a feasibility case study for skin sensitisation. Altern Lab Anim2008; 36: 557–568.
AdlerSBasketterDCretonS, et al.Alternative (non-animal) methods for cosmetics testing: current status and future prospects — 2010. Arch Toxicol2011; 85: 367–485.
27.
ReisingerKHoffmannSAlépéeN, et al.Systematic evaluation of non-animal test methods for skin sensitisation safety assessment. Toxicol in Vitro2015; 29: 259–270.
28.
CoutantKDUlrichPThomasH, et al.Early changes in murine epidermal cell phenotype by contact sensitizers. Toxicol Sci1999; 48: 74–81.
29.
CorsiniEPrimaveraAMarinovichM, et al.Selective induction of cell-associated interleukin-1α in murine keratinocytes by chemical allergens. Toxicology1998; 129: 193–200.
30.
Van OchFMMVan LoverenHVan WolfswinkelJC, et al.Assessment of potency of allergenic activity of low molecular weight compounds based on IL-1α and IL-18 production by a murine and human keratinocyte cell line. Toxicology2005; 210: 95–109.
31.
CorsiniEMitjansMGalbiatiV, et al.Use of IL-18 production in a human keratinocyte cell line to discriminate contact sensitizers from irritants and low molecular weight respiratory allergens. Toxicol Vitro Int J Publ Assoc BIBRA2009; 23: 789–796.
32.
CorsiniEGalbiatiVMitjansM, et al.NCTC 2544 and IL-18 production: a tool for the identification of contact allergens. Toxicol Vitro Int J Publ Assoc BIBRA2013; 27: 1127–1134.
33.
GalbiatiVMitjansMLucchiL, et al.Further development of the NCTC 2544 IL-18 assay to identify in vitro contact allergens. Toxicol Vitro Int J Publ Assoc BIBRA2011; 25: 724–732.
34.
Guyard-NicodemeMGeraultEPlatteelM, et al.Development of a multiparametric in vitro model of skin sensitization. J Appl Toxicol JAT2015; 35: 48–58.
35.
TeunisMCorsiniESmitsM, et al.Transfer of a two-tiered keratinocyte assay: IL-18 production by NCTC2544 to determine the skin sensitizing capacity and epidermal equivalent assay to determine sensitizer potency. Toxicol Vitro Int J Publ Assoc BIBRA2013; 27: 1135–1150.
36.
NatschAEmterR. Skin sensitizers induce antioxidant response element dependent genes: application to the in vitro testing of the sensitization potential of chemicals. Toxicol Sci Off J Soc Toxicol2008; 102: 110–119.
37.
RamirezTMehlingAKolleSN, et al.LuSens: a keratinocyte based ARE reporter gene assay for use in integrated testing strategies for skin sensitization hazard identification. Toxicol in Vitro2014; 28: 1482–1497.
38.
BelotNSimBLongmoreC, et al.Adaptation of the KeratinoSens™ skin sensitization test to animal-product-free cell culture. ALTEX2017; 34: 560–564.
39.
OECD. Test No. 442D: In vitro skin sensitisation: ARE-Nrf2 luciferase test method, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 2018, 51 pp.
40.
NatschABauchCFoertschL, et al.The intra- and inter-laboratory reproducibility and predictivity of the KeratinoSens assay to predict skin sensitizers in vitro: results of a ring-study in five laboratories. Toxicol Vitro Int J Publ Assoc BIBRA2011; 25: 733–744.
41.
EmterRvan der VeenJWAdamsonG, et al.Gene expression changes induced by skin sensitizers in the KeratinoSens™ cell line: discriminating Nrf2-dependent and Nrf2-independent events. Toxicol Vitro Int J Publ Assoc BIBRA2013; 27: 2225–2232.
42.
EmterREllisGNatschA. Performance of a novel keratinocyte-based reporter cell line to screen skin sensitizers in vitro. Toxicol Appl Pharmacol2010; 245: 281–290.
43.
NatschAEmterRGfellerH, et al.Predicting skin sensitizer potency based on in vitro data from KeratinoSens and kinetic peptide binding: global versus domain-based assessment. Toxicol Sci Off J Soc Toxicol2015; 143: 319–332.
44.
McKimJMKellerDJGorskiJR. A new in vitro method for identifying chemical sensitizers combining peptide binding with ARE/EpRE-mediated gene expression in human skin cells. Cutan Ocul Toxicol2010; 29: 171–192.
45.
ReutterKJägerDDegwertJ, et al.In vitro model for contact sensitization: II. Induction of IL-1β mRNA in human blood-derived dendritic cells by contact sensitizers. Toxicol Vitro Int J Publ Assoc BIBRA1997; 11: 619–626.
46.
PichowskiJSCumberbatchMDearman, et al.Investigation of induced changes in interleukin 1β mRNA expression by cultured human dendritic cells as an in vitro approach to skin sensitization testing. Toxicol Vitro Int J Publ Assoc BIBRA2000; 14: 351–360.
47.
PichowskiJSCumberbatchMDearmanRJ, et al.Allergen-induced changes in interleukin 1β (IL-1β) mRNA expression by human blood-derived dendritic cells: inter-individual differences and relevance for sensitization testing. J Appl Toxicol JAT2001; 21: 115–121.
48.
DegwertJSteckelFHoppeU, et al.In vitro model for contact sensitization: I. Stimulatory capacities of human blood-derived dendritic cells and their phenotypical alterations in the presence of contact sensitizers. Toxicol Vitro Int J Publ Assoc BIBRA1997; 11: 613–618.
49.
BeckerDKühnULempertzU, et al.Flow-cytometric screening for the modulation of receptor-mediated endocytosis in human dendritic cells: implications for the development of an in vitro technique for predictive testing of contact sensitizers. J Immunol Methods1997; 203: 171–180.
50.
RizovaHCarayonPBarbierA, et al.Contact allergens, but not irritants, alter receptor-mediated endocytosis by human epidermal Langerhans cells. Br J Dermatol1999; 140: 200–209.
51.
NeisiusUBrandPPlochmannS, et al.Detection of increased tyrosine phosphorylation in murine Langerhans cells after stimulation with contact sensitizers. Arch Dermatol Res1999; 291: 22–27.
52.
KühnUBrandPWillemsenJ, et al.Induction of tyrosine phosphorylation in human MHC class II-positive antigen-presenting cells by stimulation with contact sensitizers. J Immunol Baltim Md 19501998; 160: 667–673.
53.
BanerjeeGIyerVJCherianKM. A rapid in vitro method of identifying contact allergens and irritants. Toxicol Mech Methods2003; 13: 103–109.
54.
AebyPWyssCBeckH, et al.Characterization of the sensitizing potential of chemicals by in vitro analysis of dendritic cell activation and skin penetration. J Invest Dermatol2004; 122: 1154–1164.
55.
StaquetMJSportouchMJacquetC, et al.Moderate skin sensitizers can induce phenotypic changes on in vitro generated dendritic cells. Toxicol in Vitro2004; 18: 493–500.
56.
JugdéFBoissierCRougier-LarzatN, et al.Regulation by allergens of chemokine receptor expression on in vitro-generated dendritic cells. Toxicology2005; 212: 227–238.
57.
HuletteBCRyanCAGildeaLA, et al.Relationship of CD86 surface marker expression and cytotoxicity on dendritic cells exposed to chemical allergen. Toxicol Appl Pharmacol2005; 209: 159–166.
58.
AibaSTerunumaAManomeH, et al.Dendritic cells differently respond to haptens and irritants by their production of cytokines and expression of co-stimulatory molecules. Eur J Immunol1997; 27: 3031–3038.
59.
CoutantKDde FraissinetteABCordierA, et al.Modulation of the activity of human monocyte-derived dendritic cells by chemical haptens, a metal allergen, and a staphylococcal superantigen. Toxicol Sci Off J Soc Toxicol1999; 52: 189–198.
60.
TuschlHKovacR. Langerhans cells and immature dendritic cells as model systems for screening of skin sensitizers. Toxicol in Vitro2001; 15: 327–331.
61.
StraubeFGrenetOBrueggerP, et al.Contact allergens and irritants show discrete differences in the activation of human monocyte-derived dendritic cells: consequences for in vitro detection of contact allergens. Arch Toxicol2005; 79: 37–46.
62.
De SmedtACAVan Den HeuvelRLVan TendelooVF, et al.Capacity of CD34+ progenitor-derived dendritic cells to distinguish between sensitizers and irritants. Toxicol Lett2005; 156: 377–389.
63.
VerheyenGRSchoetersENuijtenJ-M, et al.Cytokine transcript profiling in CD34+-progenitor derived dendritic cells exposed to contact allergens and irritants. Toxicol Lett2005; 155: 187–194.
64.
ReuterHSpiekerJGerlachS, et al.In vitro detection of contact allergens: development of an optimized protocol using human peripheral blood monocyte-derived dendritic cells. Toxicol Vitro Int J Publ Assoc BIBRA2011; 25: 315–323.
65.
SchoetersEVerheyenGRNelissenI, et al.Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol2007; 44: 3222–3233.
66.
HooyberghsJSchoetersELambrechtsN, et al.A cell-based in vitro alternative to identify skin sensitizers by gene expression. Toxicol Appl Pharmacol2008; 231: 103–111.
67.
TrompezinskiSMigdalCTailhardatM, et al.Characterization of early events involved in human dendritic cell maturation induced by sensitizers: cross talk between MAPK signalling pathways. Toxicol Appl Pharmacol2008; 230: 397–406.
68.
SzameitSVierlingerKFarmerL, et al.Gene expression studies in cultured dendritic cells: new indicators for the discrimination of skin sensitizers and irritants in vitro. Clin Exp Allergy J Br Soc Allergy Clin Immunol2009; 39: 856–868.
69.
De SmedtACAVan Den HeuvelRLVan TendelooVFI, et al.Phenotypic alterations and IL-1β production in CD34(+) progenitor- and monocyte-derived dendritic cells after exposure to allergens: a comparative analysis. Arch Dermatol Res2002; 294: 109–116.
70.
SzameitSVierlingerKFarmerL, et al.Microarray-based in vitro test system for the discrimination of contact allergens and irritants: identification of potential marker genes. Clin Chem2008; 54: 525–533.
71.
LambrechtsNVanheelHNelissenI, et al.Assessment of chemical skin-sensitizing potency by an in vitro assay based on human dendritic cells. Toxicol Sci Off J Soc Toxicol2010; 116: 122–129.
72.
GildeaLARyanCAFoertschLM, et al.Identification of gene expression changes induced by chemical allergens in dendritic cells: opportunities for skin sensitization testing. J Invest Dermatol2006; 126: 1813–1822.
73.
ToebakMJPohlmannPRSampat-SardjoepersadSC, et al.CXCL8 secretion by dendritic cells predicts contact allergens from irritants. Toxicol Vitro Int J Publ Assoc BIBRA2006; 20: 117–124.
74.
Cluzel-TailhardatMBonnet-DuquennoyMde QueralDP, et al.Chemicals with weak skin sensitizing properties can be identified using low-density microarrays on immature dendritic cells. Toxicol Lett2007; 174: 98–109.
75.
AshikagaTHoyaMItagakiH, et al.Evaluation of CD86 expression and MHC class II molecule internalization in THP-1 human monocyte cells as predictive endpoints for contact sensitizers. Toxicol Vitro Int J Publ Assoc BIBRA2002; 16: 711–716.
76.
HirotaMMoroO. MIP-1β, a novel biomarker for in vitro sensitization test using human monocytic cell line. Toxicol Vitro Int J Publ Assoc BIBRA2006; 20: 736–742.
77.
MiyazawaMItoYYoshidaY, et al.Phenotypic alterations and cytokine production in THP-1 cells in response to allergens. Toxicol Vitro Int J Publ Assoc BIBRA2007; 21: 428–437.
78.
NukadaYMiyazawaMKosakaN, et al.Production of IL-8 in THP-1 cells following contact allergen stimulation via mitogen-activated protein kinase activation or tumor necrosis factor-alpha production. J Toxicol Sci2008; 33: 175–185.
79.
MitjansMVivianiBLucchiL, et al.Role of p38 MAPK in the selective release of IL-8 induced by chemical allergen in naive THp-1 cells. Toxicol Vitro Int J Publ Assoc BIBRA2008; 22: 386–395.
80.
LimY-MMoonS-JAnS-S, et al.Suitability of macrophage inflammatory protein-1β production by THP-1 cells in differentiating skin sensitizers from irritant chemicals. Contact Dermat2008; 58: 193–198.
81.
LambrechtsNVerstraelenSLodewyckxH, et al.THP-1 monocytes but not macrophages as a potential alternative for CD34+ dendritic cells to identify chemical skin sensitizers. Toxicol Appl Pharmacol2009; 236: 221–230.
82.
EdwardsARoscoeLLongmoreC, et al.Adaptation of the human Cell Line Activation Test (h-CLAT) to animal-product-free conditions. ALTEX2018; 35: 477–488.
83.
MariglianiBSilvaJVMABalottinLBL, et al.Adaptation of a skin sensitization assay to a chemically defined culture. Toxicol in Vitro2019; 57: 145–153.
84.
OECD. Test No. 442E: In vitro skin sensitisation: In vitro skin sensitisation assays addressing the key event on activation of dendritic cells on the adverse outcome pathway for skin sensitisation, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 2018, 65 pp.
85.
AshikagaTYoshidaYHirotaM, et al.Development of an in vitro skin sensitization test using human cell lines: the human Cell Line Activation Test (h-CLAT). I. Optimization of the h-CLAT protocol. Toxicol in Vitro2006; 20: 767–773.
86.
SakaguchiHAshikagaTMiyazawaM, et al.The relationship between CD86/CD54 expression and THP-1 cell viability in an in vitro skin sensitization test–human cell line activation test (h-CLAT). Cell Biol Toxicol2009; 25: 109–126.
87.
YoshidaYSakaguchiHItoY, et al.Evaluation of the skin sensitization potential of chemicals using expression of co-stimulatory molecules, CD54 and CD86, on the naive THP-1 cell line. Toxicol Vitro Int J Publ Assoc BIBRA2003; 17: 221–228.
88.
SakaguchiHAshikagaTMiyazawaM, et al.Development of an in vitro skin sensitization test using human cell lines; human Cell Line Activation Test (h-CLAT). II. An inter-laboratory study of the h-CLAT. Toxicol Vitro Int J Publ Assoc BIBRA2006; 20: 774–784.
89.
SakaguchiHRyanCOvigneJ-M, et al.Predicting skin sensitization potential and inter-laboratory reproducibility of a human Cell Line Activation Test (h-CLAT) in the European Cosmetics Association (COLIPA) ring trials. Toxicol Vitro Int J Publ Assoc BIBRA2010; 24: 1810–1820.
90.
NukadaYAshikagaTSakaguchiH, et al.Predictive performance for human skin sensitizing potential of the human cell line activation test (h-CLAT). Contact Dermat2011; 65: 343–353.
91.
SakaguchiHMiyazawaMYoshidaY, et al.Prediction of preservative sensitization potential using surface marker CD86 and/or CD54 expression on human cell line, THP-1.Arch Dermatol Res2007; 298: 427–437.
92.
AnSKimSHuhY, et al.Expression of surface markers on the human monocytic leukaemia cell line, THP-1, as indicators for the sensitizing potential of chemicals. Contact Dermat2009; 60: 185–192.
93.
SuzukiMHirotaMHaginoS, et al.Evaluation of changes of cell-surface thiols as a new biomarker for in vitro sensitization test. Toxicol Vitro Int J Publ Assoc BIBRA2009; 23: 687–696.
94.
ArkuszJStępnikMSobalaW, et al.Prediction of the contact sensitizing potential of chemicals using analysis of gene expression changes in human THP-1 monocytes. Toxicol Lett2010; 199: 51–59.
95.
TakahashiTKimuraYSaitoR, et al.An in vitro test to screen skin sensitizers using a stable THP-1-derived IL-8 reporter cell line, THP-G8. Toxicol Sci2011; 124: 359–369.
96.
AzamPPeifferJLChamoussetD, et al.The cytokine-dependent MUTZ-3 cell line as an in vitro model for the screening of contact sensitizers. Toxicol Appl Pharmacol2006; 212: 14–23.
97.
OuwehandKSpiekstraSWReindersJ, et al.Comparison of a novel CXCL12/CCL5 dependent migration assay with CXCL8 secretion and CD86 expression for distinguishing sensitizers from non-sensitizers using MUTZ-3 Langerhans cells. Toxicol Vitro Int J Publ Assoc BIBRA2010; 24: 578–585.
98.
WilliamsEHWilliamsCAMcLeodJD. Identification of PDL-1 as a novel biomarker of sensitizer exposure in dendritic-like cells. Toxicol Vitro Int J Publ Assoc BIBRA2010; 24: 1727–1735.
99.
JohanssonHLindstedtMAlbrektA-S, et al.A genomic biomarker signature can predict skin sensitizers using a cell-based in vitro alternative to animal tests. BMC Genomics2011; 12: 399.
100.
JohanssonHAlbrektA-SBorrebaeckCAK, et al.The GARD assay for assessment of chemical skin sensitizers. Toxicol Vitro Int J Publ Assoc BIBRA2013; 27: 1163–1169.
101.
AlbrektA-SJohanssonHBörjeA, et al.Skin sensitizers differentially regulate signaling pathways in MUTZ-3 cells in relation to their individual potency. BMC Pharmacol Toxicol2014; 15: 5.
102.
GibbsSSpiekstraSCorsiniE, et al.Dendritic cell migration assay: a potential prediction model for identification of contact allergens. Toxicol Vitro Int J Publ Assoc BIBRA2013; 27: 1170–1179.
103.
ReesBSpiekstraSWCarfiM, et al.Inter-laboratory study of the in vitro dendritic cell migration assay for identification of contact allergens. Toxicol Vitro Int J Publ Assoc BIBRA2011; 25: 2124–2134.
104.
VerrierACSchmittDStaquetMJ. Fragrance and contact allergens in vitro modulate the HLA-DR and E-cadherin expression on human epidermal Langerhans cells. Int Arch Allergy Immunol1999; 120: 56–62.
105.
RustemeyerTPreussMvon BlombergBME, et al.Comparison of two in vitro dendritic cell maturation models for screening contact sensitizers using a panel of methacrylates. Exp Dermatol2003; 12: 682–691.
106.
KimberICumberbatchMBettsCJ, et al.Dendritic cells and skin sensitisation hazard assessment. Toxicol Vitro Int J Publ Assoc BIBRA2004; 18: 195–202.
107.
PiroidCOvigneJMRoussetF, et al.The myeloid U937 skin sensitization test (U-SENS) addresses the activation of dendritic cell event in the adverse outcome pathway for skin sensitization. Toxicol in Vitro2015; 29: 901–916.
108.
AdeNMartinozzi-TeissierSPallardyM, et al.Activation of U937 cells by contact sensitizers: CD86 expression is independent of apoptosis. J Immunotoxicol2006; 3: 189–197.
109.
PythonFGoebelCAebyP. Assessment of the U937 cell line for the detection of contact allergens. Toxicol Appl Pharmacol2007; 220: 113–124.
110.
HennenJAebyPGoebelC, et al.Cross talk between keratinocytes and dendritic cells: impact on the prediction of sensitization. Toxicol Sci Off J Soc Toxicol2011; 123: 501–510.
111.
HennenJBlömekeB. Keratinocytes improve prediction of sensitization potential and potency of chemicals with THP-1 cells. ALTEX2017; 34: 279–288.
112.
CaoYPMaPCLiuWD, et al.Evaluation of the skin sensitization potential of chemicals in THP-1/keratinocyte co-cultures. Immunopharmacol Immunotoxicol2012; 34: 196–204.
113.
SchreinerMPeiserMBriechleD, et al.A loose-fit coculture of activated keratinocytes and dendritic cell-related cells for prediction of sensitizing potential. Allergy2007; 62: 1419–1428.
114.
WannerRSonnenburgAQuatchadzeM, et al.Classification of sensitizing and irritative potential in a combined in-vitro assay. Toxicol Appl Pharmacol2010; 245: 211–218.
115.
SchreinerMPeiserMBriechleD, et al.A new dendritic cell type suitable as sentinel of contact allergens. Toxicology2008; 249: 146–152.
116.
HerouetCCottinMLeClaireJ, et al.Contact sensitizers specifically increase MHC class II expression on murine immature dendritic cells. In Vitr Mol Toxicol2000; 13: 113–123.
117.
RichterASchmuckerSSEsserPR, et al.Human T cell priming assay (hTCPA) for the identification of contact allergens based on naive T cells and DC–IFN-γ and TNF-α readout. Toxicol in Vitro2013; 27: 1180–1185.
118.
MoulonCPéguet-NavarroJCourtellemontP, et al.In vitro primary sensitization and restimulation of hapten-specific T cells by fresh and cultured human epidermal Langerhans’ cells. Immunology1993; 80: 373–379.
119.
KrastevaMPeguet-NavarroJMoulonC, et al.In vitro primary sensitization of hapten-specific T cells by cultured human epidermal Langerhans cells — a screening predictive assay for contact sensitizers. Clin Exp Allergy J Br Soc Allergy Clin Immunol1996; 26: 563–570.
120.
RustemeyerTDe LigterSVon BlombergBM, et al.Human T lymphocyte priming in vitro by haptenated autologous dendritic cells. Clin Exp Immunol1999; 117: 209–216.
121.
GuironnetGDalbiez-GauthierCRoussetF, et al.In vitro human T cell sensitization to haptens by monocyte-derived dendritic cells. Toxicol in Vitro2000; 14: 517–522.
122.
RougierNRedziniakGSchmittD, et al.Evaluation of the capacity of dendritic cells derived from cord blood CD34+ precursors to present haptens to unsensitized autologous T cells in vitro. J Invest Dermatol1998; 110: 348–352.
123.
RougierNRedziniakGMouginD, et al.In vitro evaluation of the sensitization potential of weak contact allergens using Langerhans-like dendritic cells and autologous T cells. Toxicology2000; 145: 73–82.
124.
YokozekiHKatayamaINishiokaK.Experimental study for the development of an in vitro test for contact allergens. 1. Primary activation of hapten-specific T cells by hapten-conjugated epidermal cells. Int Arch Allergy Immunol1995; 106: 394–400.
125.
ArimuraMYokozekiHKatayamaI, et al.Experimental study for the development of an in vitro test for contact allergens. 2. Comparison of the in vitro sensitization test with the guinea pig maximization test for contact allergens. Int Arch Allergy Immunol1998; 115: 228–234.
126.
VocansonMCluzel-TailhardatMPoyetG, et al.Depletion of human peripheral blood lymphocytes in CD25+ cells allows for the sensitive in vitro screening of contact allergens. J Invest Dermatol2008; 128: 2119–2122.
127.
DietzLEsserPRSchmuckerSS, et al.Tracking human contact allergens: from mass spectrometric identification of peptide-bound reactive small chemicals to chemical-specific naive human T-cell priming. Toxicol Sci Off J Soc Toxicol2010; 117: 336–347.
128.
CorsiniELimiroliEMarinovichM, et al.Selective induction of interleukin-12 in reconstructed human epidermis by chemical allergens. Altern Lab Anim1999; 27: 261–269.
129.
KubilusJCannonCNealP, et al.Response of the EpiDerm skin model to topically applied irritants and allergens. In Vitro Mol Toxicol1996; 9: 157–166.
130.
CoquetteABernaNVandenboschA, et al.Differential expression and release of cytokines by an in vitro reconstructed human epidermis following exposure to skin irritant and sensitizing chemicals. Toxicol Vitro Int J Publ Assoc BIBRA1999; 13: 867–877.
131.
CoquetteABernaNVandenboschA, et al.Analysis of interleukin-1α (IL-1α) and interleukin-8 (IL-8) expression and release in in vitro reconstructed human epidermis for the prediction of in vivo skin irritation and/or sensitization. Toxicol Vitro Int J Publ Assoc BIBRA2003; 17: 311–321.
132.
dos SantosGGSpiekstraSWSampat-SardjoepersadSC, et al.A potential in vitro epidermal equivalent assay to determine sensitizer potency. Toxicol Vitro Int J Publ Assoc BIBRA2011; 25: 347–357.
133.
McKimJMJrKellerDJIIIGorskiJR. An in vitro method for detecting chemical sensitization using human reconstructed skin models and its applicability to cosmetic, pharmaceutical, and medical device safety testing. Cutan Ocul Toxicol2012; 31: 292–305.
134.
SaitoKNukadaYTakenouchiO, et al.Development of a new in vitro skin sensitization assay (Epidermal Sensitization Assay; EpiSensA) using reconstructed human epidermis. Toxicol Vitro Int J Publ Assoc BIBRA2013; 27: 2213–2224.
135.
FacyVFlouretVRégnierM, et al.Reactivity of Langerhans cells in human reconstructed epidermis to known allergens and UV radiation. Toxicol Vitro Int J Publ Assoc BIBRA2005; 19: 787–795.
136.
FacyVFlouretVRégnierM, et al.Langerhans cells integrated into human reconstructed epidermis respond to known sensitizers and ultraviolet exposure. J Invest Dermatol2004; 122: 552–553.
137.
GibbsSCorsiniESpiekstraSW, et al.An epidermal equivalent assay for identification and ranking potency of contact sensitizers. Toxicol Appl Pharmacol2013; 272: 529–541.
138.
CottrezFBoitelEAuriaultC, et al.Genes specifically modulated in sensitized skins allow the detection of sensitizers in a reconstructed human skin model. Development of the SENS-IS assay. Toxicol In vitro2015; 29: 787–802.
139.
CottrezFBoitelEOurlinJ-C, et al.SENS-IS, a 3D reconstituted epidermis based model for quantifying chemical sensitization potency: Reproducibility and predictivity results from an inter-laboratory study. Toxicol Vitro Int J Publ Assoc BIBRA2016; 32: 248–260.
140.
LeeSDongDXJindalR, et al.Predicting full thickness skin sensitization using a support vector machine. Toxicol Vitro Int J Publ Assoc BIBRA2014; 28: 1413–1423.
141.
Alloul-RamdhaniMTensenCPEl GhalbzouriA. Performance of the N/TERT epidermal model for skin sensitizer identification via Nrf2-Keap1-ARE pathway activation. Toxicol in Vitro2014; 28: 982–989.
142.
PistoorFHRambukkanaAKroezenM, et al.Novel predictive assay for contact allergens using human skin explant cultures. Am J Pathol1996; 149: 337–343.
143.
AhmedSSWangXNFieldingM, et al.An in vitro human skin test for assessing sensitization potential. J Appl Toxicol JAT2016; 36: 669–684.
144.
UchinoTTakezawaTIkarashiY. Reconstruction of three-dimensional human skin model composed of dendritic cells, keratinocytes and fibroblasts utilizing a handy scaffold of collagen vitrigel membrane. Toxicol in Vitro2009; 23: 333–337.
145.
UchinoTTakezawaTIkarashiY, et al.Construction of three-dimensional human skin model involving dendritic cells and its application to skin sensitization test. Yakugaku Zasshi2008; 128(1): 45–50.
146.
OuwehandKSpiekstraSWWaaijmanT, et al.Technical advance: Langerhans cells derived from a human cell line in a full-thickness skin equivalent undergo allergen-induced maturation and migration. J Leukoc Biol2011; 90: 1027–1033.
147.
KoeperL-MSchulzAAhrHJ, et al.In vitro differentiation of skin sensitizers by cell signaling pathways. Toxicology2007; 242: 144–152.
148.
BrunnerDFrankJApplH, et al.Serum-free cell culture: the serum-free media interactive online database. ALTEX2010; 27: 53–62.
149.
ButlerM. Serum and protein free media. In: Al-RubeaiM (ed) Cell engineering: animal cell culture, vol. 9. New York: Springer International Publishing, 2014, 223–236 pp.
KandárováHLetašiováS. Alternative methods in toxicology: pre-validated and validated methods. Interdiscip Toxicol2011; 4: 107–113.
152.
AndersonNLPolanskiMPieperR, et al.The human plasma proteome: a nonredundant list developed by combination of four separate sources. Mol Cell Proteomics2004; 3: 311–326.
153.
BakerM. Reproducibility: respect your cells!Nature2016; 537: 433–435.
154.
van der ValkJBrunnerDDe SmetK, et al.Optimization of chemically defined cell culture media: replacing fetal bovine serum in mammalian in vitro methods. Toxicol in Vitro2010; 24: 1053–1063.
155.
PricePJGregoryEA. Relationship between in vitro growth promotion and biophysical and biochemical properties of the serum supplement. In Vitro1982; 18: 576–584.
156.
VojganiYShiraziAZareiS, et al.Comparison of efficacies of fetal bovine sera from different suppliers in cell culture experiments. Comp Clin Pathol2018; 27: 519–527.
157.
PazosPBoveriMGennariA, et al.Culturing cells without serum: lessons learnt using molecules of plant origin. ALTEX2004; 21: 67–72.
158.
BurnoufTStrunkDKohMB, et al.Human platelet lysate: replacing fetal bovine serum as a gold standard for human cell propagation?Biomaterials2016; 76: 371–387.
159.
RauchCFeifelEAmannEM, et al.Alternatives to the use of fetal bovine serum: human platelet lysates as a serum substitute in cell culture media. ALTEX2011; 28: 305–316.
160.
KarnieliOFriednerOMAllicksonJG, et al.A consensus introduction to serum replacements and serum-free media for cellular therapies. Cytotherapy2017; 19: 155–169.
161.
MuragliaANguyenVTNardiniM, et al.Culture medium supplements derived from human platelet and plasma: cell commitment and proliferation support. Front Bioeng Biotechnol2017; 5: 66.
162.
UstaSNScharerCDXuJ, et al.Chemically defined serum-free and xeno-free media for multiple cell lineages. Ann Transl Med2014; 2: 97.
163.
MertenOW. Safety issues of animal products used in serum-free media. Dev Biol Stand1999; 99: 167–180.
164.
YaoTAsayamaY. Animal-cell culture media: history, characteristics, and current issues. Reprod Med Biol2017; 16: 99–117.
165.
OECD. Guidance Document on good in vitro method practices (GIVIMP). Series on Testing and Assessment No. 286. Paris, France: Organisation for Economic Co-operation and Development, 2018, 264 pp.
166.
OECD. Test No. 442D: In vitro skin sensitisation: Are-Nrf2 luciferase test method, OECD Guidelines for the Testing of Chemicals, Section 4. Paris, France: Organisation for Economic Co-operation and Development, 2015, 20 pp.
167.
ChistiY. Animal-cell damage in sparged bioreactors. Trends Biotechnol2000; 18: 420–432.
168.
SchöderMMatischakKFriedlP. Serum- and protein-free media formulations for the Chinese hamster ovary cell line DUKXB11. J Biotechnol2004; 108: 279–292.
169.
MajorekKAPorebskiPJDayalA, et al.Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. Mol Immunol2012; 52: 174–182.
AfroughBDwekMVGreenwellP. Identification and elimination of false-positives in an ELISA-based system for qualitative assessment of glycoconjugate binding using a selection of plant lectins. Biotechniques2007; 43: 458–462.
173.
ButlerM (ed) Cell culture and upstream processing, 1st ed. London, UK: Taylor & Francis, 2007, 250 pp.
KaplanMEClarkC. An improved rosetting assay for detection of human T lymphocytes. J Immunol Methods1974; 5: 131–135.
189.
AnBKaplanDLBrodskyB. Engineered recombinant bacterial collagen as an alternative collagen-based biomaterial for tissue engineering. Front Chem2014; 2: 40.
190.
DuvigneauJCSiposWHartlRT, et al.Heparin and EDTA as anticoagulant differentially affect cytokine mRNA level of cultured porcine blood cells. J Immunol Methods2007; 324: 38–47.
191.
LinhardtRJGunayNS. Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost1999; 25: 5–16.
